CureVac’s vaccine candidate only 47% effective, based on interim analysis

The messenger RNA vaccine does not meet the required criteria at this stage, said the German laboratory, which has signed a major ordering contract with the European Union.

German laboratory CureVac announced on Wednesday that its leading COVID-19 vaccine candidate had only shown 47% efficacy, according to the interim analysis of a large-scale clinical trial, and was not fulfilling at this stage. the required criteria.

The vaccine “Achieved a preliminary efficacy of 47% against COVID-19, regardless of its severity, not meeting the pre-specified statistical criteria of success”, said in a press release the laboratory which has signed a major order contract with the European Union for this messenger RNA vaccine.

To see also – Olivier Véran welcomes the launch of vaccination for 12-17 year olds


The article from the source


Related Articles

Back to top button